After stent, NPPA starts process to cap other medical devices

Next on the radar: lenses and ortho implants; Pharma lobbies wants representation in price fixing

After capping coronary stents, the National Pharmaceutical Pricing Authority (NPPA) gears up for price control of other medical devices. The NPPA met intra-ocular lens manufacturers today to discuss the matter. They will subsequently meet orthopaedic implant manufacturers this week. Both these categories of devices are under the pricing regulator's radar to bring them under price control.

Capping prices of coronary stents was the first move in slashing prices of medical devices. In February this year, the regulator slashed the prices of coronary stents by 85 per cent.

This event brought about a change in the thinking of medical device manufacturers. The CEO